Randomized elimination and prolongation of ACE inhibitors and ARBs in coronavirus 2019 (REPLACE COVID) Trial Protocol

Severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2), the virus responsible for coronavirus disease 2019 (COVID‐19), is associated with high incidence of multiorgan dysfunction and death. Angiotensin‐converting enzyme 2 (ACE2), which facilitates SARS‐CoV‐2 host cell entry, may be impacted by...

全面介紹

Na minha lista:
書目詳細資料
發表在:J Clin Hypertens (Greenwich)
Main Authors: Cohen, Jordana B., Hanff, Thomas C., Corrales‐Medina, Vicente, William, Preethi, Renna, Nicolas, Rosado‐Santander, Nelson R., Rodriguez‐Mori, Juan E., Spaak, Jonas, Andrade‐Villanueva, Jaime, Chang, Tara I., Barbagelata, Alejandro, Alfonso, Carlos E., Bernales‐Salas, Eduardo, Coacalla, Johanna, Castro‐Callirgos, Carlos Augusto, Tupayachi‐Venero, Karen E., Medina, Carola, Valdivia, Renzo, Villavicencio, Mirko, Vasquez, Charles R., Harhay, Michael O., Chittams, Jesse, Sharkoski, Tiffany, Byrd, James Brian, Edmonston, Daniel L., Sweitzer, Nancy, Chirinos, Julio A.
格式: Artigo
語言:Inglês
出版: John Wiley and Sons Inc. 2020
主題:
Covid‐19
在線閱讀:https://ncbi.nlm.nih.gov/pmc/articles/PMC7722152/
https://ncbi.nlm.nih.gov/pubmed/32937008
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/jch.14011
標簽: 添加標簽
沒有標簽, 成為第一個標記此記錄!

相似書籍